Spotlight On... Kite teams with GE in bid to lower T cell production costs through automation; Complete Genomics axes 186 staff; FDA reviews NGS alignment algorithm; and more...

Kite Pharma ($KITE) has teamed up with GE Global Research ($GE) to develop an automated production system for engineered T cell therapies. The development of such a system could help Kite control the cost of manufacturing its closely-watched autologous immuno-oncology drugs. Dendreon, a pioneer in autologous cancer treatment, was dogged by high manufacturing costs throughout its attempt to make its cancer vaccine Provenge a success. Release

> Complete Genomics revealed its reorganization will result in the loss of 186 jobs. Piece (reg. req.)

> FDA scientists reviewed an algorithm designed to align NGS data to reference genomes. Article

> Parexel ($PRXL) introduced a Impact Express, a CTMS pitched at small to mid-sized drug developers. Item

> Korean CRO C&R Research adopted Medidata Clinical Cloud. Release

> Innovate UK awarded Analytics Engines and Almac a grant to develop a bioinformatics platform. More

> FactBio set up shop to develop its Kusp knowledge management platform. News

> Veeva Systems unveiled software to support the identification of key opinion leaders. Post | More

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.